title: [Long-term survival of a patient with advanced non-small cell lung cancer on bevacizumab therapy: case report and review of the literature].
abstract: We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44,730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects.
authors.affiliation: Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.forename: Junfang
authors.initials: J
authors.lastname: Tang
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Wu
authors.forename: Yunzhong
authors.initials: Y
authors.lastname: Zhu
authors.forename: Liyan
authors.initials: L
authors.lastname: Xu
authors.forename: Heling
authors.initials: H
authors.lastname: Shi
authors.forename: Qiyi
authors.initials: Q
authors.lastname: Meng
authors.forename: Zan
authors.initials: Z
authors.lastname: Liu
authors.forename: Lili
authors.initials: L
authors.lastname: Guo
authors.forename: Hong
authors.initials: H
authors.lastname: Tao
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Li
authors.forename: Zhe
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D060046:Maintenance Chemotherapy / Q000379:methods; D008875:Middle Aged; D017741:Survivors; D013997:Time Factors; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab